Our two first-in-class and novel mode of action drug candidates are excellent pipeline generators as they both have potential applications in multiple major underserved indications (“I&I pipeline in a product”). We carefully select indications based on science, clinical unmet need and market access considerations.
We also apply our expertise in formulation and clinical practice to ensure treatment satisfaction for the patients and release of the full clinical potential of therapies
When topical dosage form is considered the right dosage form, our PAD Technology™ formulation and drug delivery system offer several unique advantages in the development of potent innovative new topical therapies for immune-mediated and inflammatory conditions, including stability, tolerability, delivery of drugs to target tissue and convenience of use in daily routines.
Patients with chronic inflammatory diseases such as psoriasis or atopic dermatitis using topical therapy have been reported to miss up to 70% of planned applications, mainly due to a lack of satisfaction with their therapy. Patients generally prefer light, moisturizing, non-greasy and quickly absorbed vehicles that are simple to use on all body parts. This is why we have developed PAD Technology™.
PAD Technology™ is used as the foundation of Wynzora® Cream for treatment of plaque psoriasis in adults and the biotech-derived non-Rx skin care line biomee™.
PAD Technology™ characteristics
PAD™ formulations are special made oil-in-water dispersions in which the internal oil phase is stabilized by encapsulation in a multimolecular robust shell structure consisting of emulsifiers, water and oil. Each PAD™ droplet maintains its own physical-chemical stability without the need of excessive presence of emulsifiers in the external water phase and can be made with several fold and up to 30-fold less emulsifiers compared to conventional emulsions with comparable oil content. The low level of emulsifier helps limit the risk of skin irritation that may otherwise be provoked by high levels of emulsifier causing extraction of lipids and damage to the epidermal barrier function.
In summary PAD Technology™ addresses the following four key areas for topical formulations:
- Chemical stability: Protects molecules from water
- Physical stability: Reduced risk of droplet collapse enables a broader formulation space for stability and solubility using non-irritating ingredients
- Tolerability: Several fold less emulsifiers compared to conventional creams and lotions
- Delivery – efficacy: Fully solubilized active ingredients in a thermodynamic form that leads to optimal delivery of actives to target tissue
For more information, please see this publication on PAD Technology™.